Neumora Therapeutics Inc. Common Stock (NMRA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Neumora Therapeutics Inc.... (NMRA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.25

-0.17 (-7.02%)

At close: Jan 14, 2025, 3:59 PM

2.24

-0.67%

Pre-market Jan 15, 2025, 06:39 AM EST

undefined% (undefined)

Bid	2.24
Market Cap	364.32M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.2
PE Ratio (ttm)	-1.88
Forward PE	n/a
Analyst	Buy

Ask	2.28
Volume	3,077,812
Avg. Volume (20D)	2,669,691
Open	2.35
Previous Close	2.42
Day's Range	2.16 - 2.38
52-Week Range	1.83 - 21.00
Beta	undefined

About NMRA

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in pa...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 15, 2023

Employees 124

Stock Exchange NASDAQ

Ticker Symbol NMRA

Website https://www.neumoratx.com

Analyst Forecast

According to 6 analyst ratings, the average rating for NMRA stock is "Buy." The 12-month stock price forecast is $21.5, which is an increase of 853.44% from the latest price.

Buy 83.33%

Hold 16.67%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+14.29%

Neumora Therapeutics shares are trading higher. B ... Unlock content with Pro Subscription

1 week ago · Source

-81.42%

Neumora Therapeutics shares are trading lower after the company announced its Phase 3 KOASTAL study did not demonstrate statistically significant improvement on its primary endpoint.

News

1 week ago · zacks.com

Neumora Stock Hits Record Low on Depression Drug Study Failure

NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.

1 week ago · businesswire.com

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

LOS ANGELES--(BUSINESS WIRE)--Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA.

1 week ago · youtube.com

Neumora's depression drug fails trial, sinking shares

CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.

1 week ago · proactiveinvestors.com

Neumora Therapeutics shares plummet as Phase 3 depression drug trial disappoints

Neumora Therapeutics shares tumbled over 83% on Thursday after its experimental drug for major depressive disorder (MDD), navacaprant, failed to demonstrate significant benefits in the pivotal Phase 3...

1 week ago · investopedia.com

Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals

Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet i...

1 week ago · marketwatch.com

Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals

News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials

1 week ago · investors.com

Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops

Neumora Therapeutics stock collapsed Thursday after its experimental depression treatment failed in the first of three studies. The post Neumora Therapeutics Stock Crashes 83% After Depression Drug Fl...

1 week ago · reuters.com

Neumora Therapeutics' depression drug fails to meet main goal of late-stage study

Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study.

3 weeks ago · seekingalpha.com

Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck

Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed signifi...

2 months ago · marketwatch.com

This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for majo...

2 months ago · seekingalpha.com

Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript

Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – P...